

Alayed K (2013) TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. *Am J Hematol* 88: 1055-61

Boiocchi L. (2013) BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. *Blood* 122: 296-7

Busfield SJ. (2014) Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. *Leukemia* 28: 2213-21

Ceribelli M. (2016) A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. *Cancer Cell* 30: 764-778

Chaperot L. (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. *Blood* 97: 3210-7

Chaperot L. (2004) Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. *Eur J Immunol* 34: 418-26

Cota C. (2010) Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. *Am J Surg Pathol* 34: 75-87

Dalle S. (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? *Br J Dermatol* 162: 74-9

Dargent JL. (2011) Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. *J Cutan Pathol* 38: 893-8

Dietrich S. (2011) Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. *Biol Blood Marrow Transplant* 17: 1250-4

Dijkman R. (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. *Blood* 109: 1720-7

Facchetti F. (2009) Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. *Haematologica* 94: 285-8

Facchetti F. (2003) Neoplasms derived from plasmacytoid monocytes/interferon-producing cells: variability of CD56 and granzyme B expression. *Am J Surg Pathol* 27: 1489-92

Facchetti F. (2016) Neoplasms derived from plasmacytoid dendritic cells. *Mod Pathol* 29: 98-111

Feuillard J. (2002) Clinical and biologic features of CD4(+)/CD56(+) malignancies. *Blood* 99: 1556-63

Frankel AE. (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. *Blood* 124: 385-92

Garnache-Ottou F. (2009) Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. *Br J Haematol* 145: 624-36

- Gopcsa L. (2005) Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells. *Eur J Haematol* 75: 346-51
- Heinicke T. (2015) Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation--a single center experience. *Ann Hematol* 94: 283-7
- Herling M. (2007) CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. *Am J Clin Pathol* 127: 687-700
- Herling M. (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. *Blood* 101: 5007-9
- Jacob MC. (2003) CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. *Haematologica* 88: 941-55
- Jardin F. (2011) TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. *Br J Haematol* 153: 413-6
- Jaye DL. (2006) Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. *Mod Pathol* 19: 1555-62
- Jegalian AG. (2010) Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. *Haematologica* 95: 1873-9
- Jegalian AG. (2009) Plasmacytoid dendritic cells: physiologic roles and pathologic states. *Adv Anat Pathol* 16: 392-404
- Julia F. (2014) Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. *Am J Surg Pathol* 38: 673-80
- Julia F. (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. *Br J Dermatol* 169: 579-86
- Kazakov DV. (2003) Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? *Br J Dermatol* 149: 869-76
- Khoury JD. (2002) CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. *Cancer* 94: 2401-8
- Leroux D. (2002) CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogique Haeamatologique. *Blood* 99: 4154-9
- Lucioni M. (2011) Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. *Blood* 118: 4591-4
- Marafioti T. (2008) Novel markers of normal and neoplastic human plasmacytoid dendritic cells. *Blood* 111: 3778-92
- Martin-Martin L (2015) Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. *Oncotarget* 6:19204-16.

Massone C. (2004) Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. *Am J Surg Pathol* 28: 719-35

Menezes J. (2014) Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. *Leukemia* 28: 823-9

Montes-Moreno S. (2013) SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. *Blood* 121: 643-7

Pagano L. (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. *Haematologica* 98: 239-46

Petrella T. (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. *Am J Clin Pathol* 123: 662-75

Petrella T. (2002) 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. *Am J Surg Pathol* 26: 852-62

Petrella T. (1999) CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanés (GFELC). *Am J Surg Pathol* 23: 137-46

Petrella T. (2004) TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. *Am J Clin Pathol* 122: 307-13

Pileri SA. (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. *Leukemia* 21: 340-50

Pilichowska ME. (2007) CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. *Am J Clin Pathol* 128: 445-53

Rauh MJ. (2012) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. *Leuk Res* 36: 81-6

Roos-Weil D. (2013) Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. *Blood* 121: 440-6

Sapienza MR. (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF- $\kappa$ B pathway inhibition. *Leukemia* 28: 1606-16

Stenzinger A. (2014) Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. *Oncotarget* 5: 6404-13

Trimoreau F. (2003) The CD4+ CD56+ CD116- CD123+ CD45RA+ CD45RO- profile is specific of DC2 malignancies. *Haematologica* 88: ELT10

Tsagarakis NJ. (2010) Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. *Leuk Res* 34: 438-46

Urosevic M, Conrad C, Kamarashev J, Asagoe K, Cozzio A, Burg G, Dummer R (2005) CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. *Hum Pathol* 36: 1020-4

Vermi W, Facchetti F, Rosati S, Vergoni F, Rossi E, Festa S, Remotti D, Grigolato P, Massarelli G, Frizzera G (2004) Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. *Am J Surg Pathol* 28: 585-95

Wiesner T. (2010) Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. *J Invest Dermatol* 130: 1152-7